TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Outcomes After Colon Surgery: Role of Prehabilitation Facilitating the Recovery Process.
Brief Summary: Most patients find that recovering from surgery is difficult particularly after abdominal surgery for cancer or other intestinal disorders. The surgical stress, healing process and concerns if further treatments are required suggest that the post-operative period may not be the best time to get people to exercise to rehabilitate lost functions. Prehabilitation is the process of enhancing functional capacity of the individual to enable him or her to withstand an incoming stressor, such as surgery, and this study aims to evaluate the effectiveness of prehabilitation for colorectal surgery. Two groups will be formed by a random process and the prehabilitation group will use an exercise cycle and weights to build endurance and strength for a 3-week period prior to surgery. The other group will receive training about exercises that will help them move better after surgery. People who are malnourished prior to surgery will receive nutritional supplements. The results of this trial will be used to inform practitioners and patients alike of the benefits (or risks if any) of exercise in preparing for surgery.


Options:
A: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise
C: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
D: Arm Label: multimodal prehabilitation begun preop; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal prehabilitation | Arm Label: Multimodal prehabilitation begun postop; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: multimodal prehabilitation | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): multimodal prehabilitation begun preop | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): Multimodal prehabilitation begun postop

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia
Brief Summary: This phase II trial is studying how well giving lenalidomide together with prednisone works in treating patients with myelofibrosis. Lenalidomide may stop the growth of myelofibrosis by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with prednisone may kill more cancer cells.


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy (BAT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Available Therapy (BAT) | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Best Available Therapy (BAT); Assigned to Arm(s): Best Available Therapy (BAT)
B: Arm Label: Treatment (lenalidomide, prednisone); Type: EXPERIMENTAL; Interventions: Drug: lenalidomide, Drug: prednisone, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (lenalidomide, prednisone)
C: Arm Label: CEP-701; Type: EXPERIMENTAL; Interventions: Drug: CEP-701 | Intervention Type: DRUG; Name: CEP-701; Assigned to Arm(s): CEP-701
D: Arm Label: Ruxolitinib 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib 5 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin followed by surgery and radiation therapy works in treating patients with malignant pleural mesothelioma.


Options:
A: Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy
B: Arm Label: single arm of Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm of Tremelimumab
C: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
D: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pemetrexed disodium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modifying Group Therapy for Bipolar Abusers
Brief Summary: The purpose of this study is to modify Integrated Group Therapy (IGT), which is has been found successful for patients with bipolar disorder (BD) and substance use disorder(SUD), so that it can be more readily adopted by community drug abuse treatment programs. IGT is being reduced from 20 to 12 sessions in this trial, and is being conducted by front-line drug counselors, to test its effectiveness in a more community-based setting. The training has been expanded so that counselors without much psychopathology training or cognitive behavioral therapy experience can conduct IGT.


Options:
A: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
B: Arm Label: IMR program; Type: EXPERIMENTAL; Interventions: Behavioral: Illness Management and Recovery (IMR) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Illness Management and Recovery (IMR); Assigned to Arm(s): IMR program
C: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard Care | Arm Label: Contingency management for abstinence from drugs; Type: EXPERIMENTAL; Interventions: Behavioral: contingency management | Intervention Type: BEHAVIORAL; Name: contingency management; Assigned to Arm(s): Contingency management for abstinence from drugs | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Brief Marijuana Intervention for Adolescent Women
Brief Summary: The purpose of this study is to examine the efficacy of a brief motivational intervention on marijuana use and sex-risk behavior in young women.


Options:
A: Arm Label: Computerized Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Computerized brief intervention | Arm Label: Counselor delivered brief intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselor delivered brief intervention | Intervention Type: BEHAVIORAL; Name: Computerized brief intervention; Assigned to Arm(s): Computerized Brief Intervention | Intervention Type: BEHAVIORAL; Name: Counselor delivered brief intervention; Assigned to Arm(s): Counselor delivered brief intervention
B: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: control group; Type: OTHER; Interventions: Behavioral: Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): control group, intervention group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention using motivational interviewing | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief intervention using motivational interviewing; Assigned to Arm(s): 1
D: Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychosocial Research to Improve Drug Treatment in Pregnancy (PRIDE-P)
Brief Summary: The purpose of this study is... To assess whether a behavioral treatment that combines motivational enhancement and cognitive skills training therapy (MET-CBT) is more effective than brief advice in: 1) decreasing use of a full range of psychoactive substances (e.g. marijuana, cocaine, methamphetamines, alcohol, nicotine, opioids) in pregnant substance using and dependent women; 2) decreasing HIV risk behavior; 3) improving birth outcomes (longer gestations and greater birth weight).


Options:
A: Arm Label: Brief Strategic Family Therapy (BSFT); Type: EXPERIMENTAL; Interventions: Behavioral: Brief Strategic Family Therapy (BSFT) | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Brief Strategic Family Therapy (BSFT); Assigned to Arm(s): Brief Strategic Family Therapy (BSFT) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual (TAU)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Cognitive Behavioral Therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Twelve Step Facilitation Therapy | Intervention Type: BEHAVIORAL; Name: Integrated Cognitive Behavioral Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Twelve Step Facilitation Therapy; Assigned to Arm(s): 2
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Arm Label: physical activity program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Intervention Type: BEHAVIORAL; Name: Exercise and counseling (for smoking cessation and physical activity); Assigned to Arm(s): Control, physical activity program
D: Arm Label: MI-CBT; Type: EXPERIMENTAL; Interventions: Behavioral: MI-CBT | Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice | Intervention Type: BEHAVIORAL; Name: MI-CBT; Assigned to Arm(s): MI-CBT | Intervention Type: BEHAVIORAL; Name: Brief Advice; Assigned to Arm(s): Brief Advice

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintenance Psychotherapies in Recurrent Depression: Study II
Brief Summary: This study will evaluate the effectiveness of maintenance interpersonal psychotherapy (IPT) in preventing relapse of depression in women who have required combined psychotherapy and pharmacotherapy treatment to obtain a remission of depression symptoms.


Options:
A: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work
B: Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: Mindfulness-based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Cognitive Therapy, Biological: Standard psychiatric care | Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy, Biological: Standard psychiatric care | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard psychiatric care | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Cognitive Therapy; Assigned to Arm(s): Mindfulness-based Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: The Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BIOLOGICAL; Name: Standard psychiatric care; Assigned to Arm(s): CBASP, Mindfulness-based Cognitive Therapy, Treatment-as-usual
D: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study Investigating Basiliximab in Combination With MMF, Cyclosporine Microemulsion and Prednisone in the Prevention of Acute Rejection in Pediatric Renal Allograft Recipients
Brief Summary: The aim of this study is assess the safety and efficacy of the treatment regimen of basiliximab ,cyclosporine microemulsion, MMF, and prednisone combined compared to cyclosporine microemulsion, MMF and prednisone in the time to first biopsy proven acute rejection episode or treatment failure during the first 6 months post-transplantation in pediatric renal allograft recipients.


Options:
A: Arm Label: Basiliximab; Type: EXPERIMENTAL; Interventions: Drug: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) | Arm Label: Basiliximab-free; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMF, cyclosporine, steroids | Intervention Type: DRUG; Name: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent); Assigned to Arm(s): Basiliximab | Intervention Type: DRUG; Name: MMF, cyclosporine, steroids; Assigned to Arm(s): Basiliximab-free
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Arm Label: 1 Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simulect (basliximab) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)] | Intervention Type: BIOLOGICAL; Name: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simulect (basliximab); Assigned to Arm(s): 1 Control
D: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder
Brief Summary: This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (ADHD).


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mixed Amphetamine Salts; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Behavior Management Training with Parents; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder
Brief Summary: This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (ADHD).


Options:
A: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
B: Arm Label: Placebo First, then ORADUR®; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo First, then ORADUR® | Arm Label: ORADUR® First, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: ORADUR® First, then Placebo | Intervention Type: DRUG; Name: Placebo First, then ORADUR®; Assigned to Arm(s): Placebo First, then ORADUR® | Intervention Type: DRUG; Name: ORADUR® First, then Placebo; Assigned to Arm(s): ORADUR® First, then Placebo
C: Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mixed Amphetamine Salts; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Behavior Management Training with Parents; Assigned to Arm(s): N/A
D: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Brief Summary: The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Intervention Type: DRUG; Name: teriflunomide (HMR1726); Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg
C: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
D: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg

Answer: B